Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

The Food and Drug Administration (FDA) says data from an ongoing safety review of oral bisphosphonates, such as Fosamax, prescribed for the treatment of bone loss, do not appear to be related to an increased risk of thigh fractures. However, the agency is telling health care professionals to be aware of a possible risk of atypical subtrochanteric femur fractures in patients using bisphosphonates.

The ongoing safety review was initiated in June 2008, following published case reports of this specific type of thigh fracture in patients with osteoporosis taking bisphosphonates. The agency says it will continue to study this issue along with a team of outside experts, which includes members of the American Society of Bone and Mineral Research Subtrochanteric Femoral Fracture Task Force.

Read the rest of this entry »

A West Liberty, Iowa, doctor is urging members of his hometown to follow a good diet and do weight-bearing exercise in lieu of taking medications to remedy ailments such as low bone density. Dr. Carl Gillman with West Liberty Chiropractic Center posed his argument in a recent issue of the West Liberty Index.

Read the rest of this entry »

The Food and Drug Administration (FDA) is going to be taking another look at Fosamax and other bone building drugs because they could be causing irregular heartbeats in some patients.

Read the rest of this entry »